Skip to main content
padlock icon - secure page this page is secure

[11C]Meta-Hydroxyephedrine PET/CT

Buy Article:

$68.00 + tax (Refund Policy)

Aim of the present review is to report the use of Positron Emission Tomography (PET) with [11C]- metahydroxyephedrine ([11C]mHED) in different clinical conditions, including heart failure, coronary artery disease, arrhythmogenic disorders, diabetes mellitus, idiopathic Parkinson's disease and adrenal tumors.

[11C]mHED is a radio-labeled neurotransmitter PET tracer used to evaluate global and regional sympathetic presynaptic innervation in vivo, and firstly carried out in cardiac tissue in the 1990s. After the radiosynthesis and the injection of 740MBq of [11C]mHED with 2±0.5 Ci/μmole specific activity, the tracer is avidly retained in myocardium within 10 minutes and remains entrapped for at least 60 minutes. The transplanted heart is a good model to evaluate specificity of tracers for presynaptic innervation whose involvement in heart failure has been characterized in several studies using PET and [11C]mHED. In addition to transplanted heart, PET and [11C]mHED prognostic value has been also assessed in Diabetes Mellitus cardiac neuropathy and in neurological disorders related to Idiopathic Parkinson's disease. Neuronal imaging by PET may be also useful in determining the risk of sudden death in patients with viable but denervated myocardium after an infarction. In addition to the evaluation of neuronal cardiac disorders, PET with [11C]mHED has been proposed in oncological studies for the detection of adrenal tumors.



No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cardiac Neuropathy; Coronary Artery Disease; Dopamine; Heart Failure; L-DOPA; Mellitus cardiac neuropathy; Myocardial ROI; Myocardial activity; Neuronal imaging; Nuclear Medicine; PET; PET/CT; Positron Emission Tomography; Radioactive Tracer; Transplanted Heart; UV detector; [11C]Meta-Hydroxyephedrine PET/CT; [11C]methane; [11C]methyl; adrenal tumor; adrenal tumors; anhydrous DMF; beta-hydroxylase; catecholamine O -methyltransferase; cocaine; coronary artery disease; de-sipramine; desipramine blockade; diabetes mellitus; gas phase; heart disease; hydroxyephedrine; idiopathic Parkinson's disease; metaraminol; mono-amine oxidase; neurological disorders; neuron; neuronal norepinephrine transporter; neurotransmitter PET tracer; norepinephrine; oncology; phenol; pre-synaptic nerve terminals; presynaptic innervation; radiolabeling; retention index; reversed phase HPLC; sympathetic system; t12neuronal imaging; vesicular monoamine transporter; wet method

Document Type: Research Article

Publication date: October 1, 2010

More about this publication?
  • Current Radiopharmaceuticals publishes original research articles, letters, reviews, drug clinical trial studies and guest edited issues on all aspects of research and development of radiolabelled compound preparations. The scope of the journal covers the following areas: radio imaging techniques, therapies; preparation and application of radionuclide compounds including the incorporation of tracer methods used in scientific research and applications.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more